Immatics N.V. (IMTX): Price and Financial Metrics


Immatics N.V. (IMTX): $7.92

0.11 (+1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMTX POWR Grades

  • Value is the dimension where IMTX ranks best; there it ranks ahead of 98.69% of US stocks.
  • The strongest trend for IMTX is in Quality, which has been heading down over the past 177 days.
  • IMTX's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).

IMTX Stock Summary

  • Of note is the ratio of IMMATICS NV's sales and general administrative expense to its total operating expenses; merely 11.24% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, IMMATICS NV is reporting a growth rate of -143.75%; that's higher than only 10.83% of US stocks.
  • Revenue growth over the past 12 months for IMMATICS NV comes in at 362.96%, a number that bests 97.34% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IMMATICS NV are CRNX, SRRK, ARBE, ARCT, and AFMD.
  • Visit IMTX's SEC page to see the company's official filings. To visit the company's web site, go to www.immatics.com.

IMTX Price Target

For more insight on analysts targets of IMTX, see our IMTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.94 Average Broker Recommendation 1.17 (Strong Buy)

IMTX Stock Price Chart Interactive Chart >

Price chart for IMTX

IMTX Price/Volume Stats

Current price $7.92 52-week high $13.60
Prev. close $7.81 52-week low $5.75
Day low $7.70 Volume 167,000
Day high $8.00 Avg. volume 230,889
50-day MA $9.39 Dividend yield N/A
200-day MA $9.62 Market Cap 603.72M

Immatics N.V. (IMTX) Company Bio


Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.


IMTX Latest News Stream


Event/Time News Detail
Loading, please wait...

IMTX Latest Social Stream


Loading social stream, please wait...

View Full IMTX Social Stream

Latest IMTX News From Around the Web

Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.

Have you been able to find a good deal on Immatics N.V.’s shares?

As of Friday, Immatics N.V.’s (NASDAQ:IMTX) stock closed at $8.51, down from $8.75 the previous day. While Immatics N.V. has underperformed by -2.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMTX fell by -34.34%, with highs and lows ranging from $14.00 to $5.75, whereas the […]

US Post News | December 26, 2022

Immatics Looks Poised For A Rebound (NASDAQ:IMTX)

Immatics draws attention from traders trying to monetize the Ups and Downs. See why IMTX stock will likely continue to experience large swings in its price.

Seeking Alpha | December 21, 2022

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended September 30, 2022.

GlobeNewswire | November 17, 2022

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase 1b; confirmed responses seen across different solid tumor types: cutaneous melanoma, ovarian cancer, head and neck cancer, uveal melanoma, and synovial sarcomaFirst patient treated with IMA203CD8, a 2nd generation ACTengine® TCR-T monotherapy product candidate targeting PRAME in Phase 1b expansion

Yahoo | November 17, 2022

Immatics Rises on $110M Underwritten Offering

Shares of biopharmaceutical company Immatics (NASDAQ:IMTX) are rising today after the company announced an underwritten stock offering of $110 million. Immatics is offering ~10.9 million common shares at $10.09 apiece. The offer closes on October 12. Despite today’s gains, Immatics shares are still down 21.5% over the past month.

Kailas Salunkhe on TipRanks | October 10, 2022

Read More 'IMTX' Stories Here

IMTX Price Returns

1-mo -2.34%
3-mo -31.61%
6-mo -28.65%
1-year -16.89%
3-year -25.28%
5-year N/A
YTD -9.07%
2022 -35.19%
2021 24.56%
2020 N/A
2019 0.00%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7409 seconds.